top of page

STIFEL 2026: Alkermes' new CEO Blair Jackson describes his priorities for the company - which include a heavy focus on the emerging orexin agonist class

9 minutes ago

1 min read

He describes the profile of the company's orexin and its development path (a key trial in Idiopathic Hypersomnia will be reading out soon), which also includes indications like ADHD, MS, and Parkinson's further on down the line. Plus how the acquisition of Avadel has been a fit, and whether he would consider doing additional deals.

https://vimeo.com/1245555477?share=copy&fl=sv&fe=ci

Coverage brought to you by

Recent Posts

See All

STIFEL 2026: Korsana Biosciences is using a proprietary brain shuttle and a beta amyloid targeting therapy and aims to take Alzheimer's treatment to the next level

BIO-Europe 2026: Envisagenics is harnessing RNA splicing as its therapeutic approach - which may open up biology to novel targets

BIO-Europe 2026: Atrogi aims to harness beta-2 agonism to increase muscle mass for a whole host of conditions, including muscle loss due to GLP medicines

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

Learn more